CJC-1295 without DAC

Growth hormone Research only Human trials

Also called Modified GRF (1-29), Mod GRF, Tetrasubstituted GRF (1-29), CJC-1295 no DAC

A 29-amino-acid version of growth-hormone-releasing hormone (GHRH) with four amino acids swapped to make it harder to break down. It signals the pituitary to release growth hormone in pulses. 'Without DAC' means it lacks the add-on that gives the DAC version a multi-day half-life.

Evidence at a glance

Evidence: Human trials — Studied in people
Status: Research compound only
Dosing: A dose has been tested in humans

Studied for hormone response, not for outcomes like body composition or recovery. Be careful with identifiers: public databases conflate this with the DAC version — PubChem CID 56841945 is labelled "CJC 1295 with DAC" but carries this compound's molecular weight (3367.9), not the DAC form's (3647.2). Vendors mislabel the two constantly, so check the weight rather than the name.

What studies report

Pulses of growth hormone release in human pharmacology studies
Raised IGF-1 in combination studies with ghrelin-receptor peptides

How it works

Binds pituitary GHRH receptors to stimulate the body's own pulsatile growth hormone release, leaving normal feedback control intact.

Binds a receptor on the cell surface and signals inward

Where it acts

Pituitary gland

The library groups this compound under Growth hormone. The diagram shows that target, not every tissue it reaches.

Illustrated

A human hypothalamus-pituitary stalk close-up anatomical view.

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Lean muscle preservationFat lossTissue repairSleep qualityGrowth hormone releaseBody composition

Reasons people seek it out — not a list of proven effects.

In practice Unapproved use

Almost always paired with ipamorelin rather than used alone
Taken before bed to align with natural growth hormone release
Often run five days on, two off

Reported real-world use, not evidence and not a recommendation.

Dosing

What was tested Evidence

100 mcg, subcutaneousHuman pharmacology studies, often alongside a GHRP→ Pulsatile GH release; IGF-1 rise with repeated use

What people report using Not evidence

100 mcg, typically before bed
Paired with ipamorelin rather than used alone

Reported for reference, not as instruction. Nothing here is a recommendation to take anything, and most of these compounds are not approved for human use.

Status: Research compound. Not approved.

Route: Subcutaneous injection, from reconstituted lyophilised powder
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Formula: C152H252N44O42
Molecular weight: 3367.9 g/mol
CAS: 863288-34-0
Available as: 5 mg

View on PubChem →

Search PubMed for CJC-1295 without DAC → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Compared with

vs CJC-1295 (with DAC) →

Side-by-side pages for the compounds this one is most often confused with or taken alongside.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.